ClinicalTrials.gg
TerminatedNCT03883607Updated Oct 28, 2021Results posted

Elafibranor, PK and Safety in Children and Adolescents 8 to 17 Years of Age With Non Alcoholic Steatohepatitis (NASH)

A Phase 2 interventional study of Elafibranor 80mg and Elafibranor 120mg in Non Alcoholic Steatohepatitis, sponsored by Genfit. Terminated at 2 sites in United States. Open to participants aged 8 Years to 17 Years. Per ClinicalTrials.gov, last updated 2021-10-28.

Sponsored by Genfit · Phase 2, Interventional, and Treatment

Why this study was terminated
Due to lack of efficacy (but not due to safety) in a Phase 3 trial of elafibranor in adult participants with NASH and fibrosis, this study in pediatric NASH was prematurely terminated

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
10
Allocation
Randomized
Ages
8 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States — 60 open to participants now, 93 under way, 13 of them phase 3. Non-alcoholic Fatty Liver Disease · United States.

Enrollment
414th of 460
10 · median 56
Started
2019
with 61 others
Phase 2
192 of 547
15 open now
Registered
279th of 547
by date

Among the 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States, this one is the 414th largest by enrollment of the 460 interventional ones that give a count, is one of 62 that started in 2019, is one of 192 in phase 2, and was the 279th registered.

Non-alcoholic Fatty Liver Disease

1,617 studies on the registry are indexed under Non-alcoholic Fatty Liver Disease; 322 are open to participants now.

Browse Non-alcoholic Fatty Liver Disease studies →

Open to participants now

60 of the 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States are open now. Recruiting first, the newest first:

55 more — sign in →

All 60 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 219 Non-alcoholic Fatty Liver Disease studies recruiting now, 66 (30%) set no upper age limit and 124 (57%) stop at 75 or younger; 27 take children under 18; 55 take healthy volunteers.

This study: 8 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States, or all of them as a file.
02

Study summary

The study was being conducted in order to assess the pharmacokinetics and the safety of elafibranor following once daily administration of two dose levels of elafibranor (80 milligrams [mg] and 120mg) during 3 months in children and adolescent population (8 to 17 years of age) with non alcoholic steatohepatitis (NASH).

03

Conditions studied

  • Non Alcoholic Steatohepatitis

Keywords

  • Pediatric
  • Pharmacokinetics
04

Who can participate

Ages eligible
8 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Was male or female between 8 and 17 years of age (inclusive) at the time of Screening Visit (when consent for study participation is given) and at the time of Randomization;
  • Diagnosis of NASH confirmed by histological evaluation (with or without fibrosis) from a liver obtained within 24 months prior to Randomization;
  • Had an (ALT) level greater than (>) 50 international units per liter (IU/L), at Screening;
  • Had a Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) greater than or equal to (>=) 5, at Screening;
  • Had a z-score (BMI z-score) (also referred to as BMI-for-age percentile) >=85th percentile for age and gender at Screening;
  • Had a (HbA1c) less than or equal (\<=) to 8.5%. If the participants had Type 2 diabetes and is taking anti-diabetic therapy (e.g., metformin or insulin), treatment must had been started at least 3 months prior to Screening and the dose must had been stable for at least 3 months prior to Screening and should remain stable through Randomization;
  • Sexually active female participants of must had agree to utilize a highly effective method of per the Clinical Trial Facilitation Group Guidelines from Screening through 30 days after the last dose of study drug (1 month after the end of treatment), and agree to monthly pregnancy testing during the study up to and including end of study.

Other inclusion criteria may apply

Exclusion criteria

Exclusion Criteria:

  • Had history of bariatric surgery or planned surgery during the study period;
  • Had known history of heart disease;
  • Had uncontrolled hypertension evidenced by sustained elevation in systolic blood pressure greater than140 mmHg or diastolic blood pressure greater than 90 mmHg despite treatment with antihypertensive therapy, prior to Randomization;
  • Had a known history of Type 1 diabetes;
  • Had a known history of acquired immunodeficiency syndrome or positive screening for antibodies at Screening Visit;
  • Had a documented weight loss of more than 5% during the 6-month period prior to Randomization;
  • Had a history of renal disease defined as an estimated (eGFR) less than 90 mL/min/1.73 m\^2 using the Schwartz Bedside GFR Calculator for Children or present at Screening Visit;
  • History of, significant alcohol consumption or inability to reliably quantify alcohol intake, and/or use of illicit drugs.
  • Had clinical and/or historical evidence of cirrhosis, included by not limited to:

    1. Abnormal (with the exception of females with a documented history of a low hemoglobin during menstruation);
    2. White blood cell count less than 3,500 cells/mm\^3 of blood;
    3. count less than150,000 cells/mm\^3 of blood;
    4. Direct greater than 0.3 mg/dL;
    5. Total bilirubin greater than 1.3 mg/dL unless the patient has a diagnosis of Gilbert disease in which case direct bilirubin, reticulocyte count and haemoglobin must be normal;
    6. Serum albumin less than 3.5 g/dL;
    7. (INR) greater than 1.4;
  • Has evidence of chronic liver disease other than NASH, defined by any one of the following:

    1. consistent with histological evidence of hepatitis;
    2. Serum hepatitis A antibody positive;
    3. Serum surface antigen positive;
    4. Serum antibody positive;
    5. Serum hepatitis E antibody positive;
    6. History of or current positive Anti-Mitochondrial Antibody Test;
    7. Known or current Iron/total iron binding capacity ratio (transferrin saturation) greater than 45% with histological evidence of iron overload;
    8. Known or current Alpha-1-antitrypsin phenotype/genotype ZZ or SZ;
    9. Diagnosis of Wilson's disease;
  • Had and/or ALT greater than 8 fold the ;
  • Was pregnant, lactating or is planning to become pregnant during the study;

Other exclusion criteria may apply

Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
10 participants (actual)

Study arms

  • Experimental
    Elafibranor 80 mg

    Participants received Elafibranor 80 mg tablet orally once daily for 12 weeks.

    Drug: Elafibranor 80mg

  • Experimental
    Elafibranor 120 mg

    Participants received Elafibranor 120 mg tablet orally once daily for 12 weeks.

    Drug: Elafibranor 120mg

Interventions

  • Once daily oral intake of elafibranor 80 mg during 3 months

    Also known as: GFT505

  • Once daily oral intake of elafibranor 120 mg during 3 months

    Also known as: GFT505

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics (PK): Maximum Observed Plasma Concentration (Cmax) of Elafibranor and Its Active Metabolite (GFT1007)

    Cmax was defined as maximum observed plasma concentration.

    Time frame: Day 1: at pre-dose; Day 29: at pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8 hours post dose; Day 30 and 85: at 24 hours after previous day dose administration

  2. Pharmacokinetics: Time to Maximum Observed Plasma Concentration (Tmax) of Elafibranor and Active Metabolite (GFT1007)

    Tmax was defined as time to reach maximum observed plasma concentration.

    Time frame: Day 1: at pre-dose; Day 29: at pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8 hours post dose; Day 30 and 85: at 24 hours after previous day dose administration

  3. Pharmacokinetics: Area Under The Plasma Concentration-time Curve From 0 to 24 Hours (AUC0-24) of Elafibranor and Active Metabolite (GFT1007)

    AUC0-24 defined as the area under the plasma concentration versus time curve of the study drug from time 0 to 24 hours.

    Time frame: Day 1: at pre-dose; Day 29: at pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8 hours post dose; Day 30 and 85: at 24 hours after previous day dose administration

  4. Pharmacokinetics: Terminal Elimination Half-life ( t½) of Elafibranor and Active Metabolite (GFT1007)

    Plasma t1/2 was defined as the time taken by drug to reduce to half of its initial plasma concentration.

    Time frame: Day 1: at pre-dose; Day 29: at pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8 hours post dose; Day 30 and 85: at 24 hours after previous day dose administration

  5. Pharmacokinetics: Plasma Trough Concentrations (Ctrough) of Elafibranor and Active Metabolite (GFT1007)

    Ctrough was defined as the plasma concentration of study drug observed just before treatment administration during repeated dosing.

    Time frame: Pre-dose on Day 1 and 29

Secondary outcomes

  1. Pharmacodynamics (PD) - Liver Markers: Change From Baseline in Serum Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Gamma-glutamyl Transferase (GGT), and Alkaline Phosphatase (ALP) at Days 15, 29, 57, 85, and 113

    Baseline was defined as the last measurement before first intake of study treatment on Day 1. Missing data were not imputed for the analysis. Normal range at screening: AST: 0 - 39 international units per liter (IU/L), ALT: 5 - 30 IU/L, GGT: 2 - 24 IU/L, and ALP: 74 - 390 IU/L.

    Time frame: Baseline (Day 1), Days 15, 29, 57, 85, and 113

  2. Pharmacodynamics - Other Liver Markers: Change From Baseline in Adiponectin at Days 29, 57, 85, and 113

    Baseline was defined as the last measurement before first intake of study treatment on Day 1. Missing data were not imputed for the analysis.

    Time frame: Baseline (Day 1), Days 29, 57, 85, and 113

  3. Pharmacodynamics - Other Liver Markers: Change From Baseline in Cytokeratin 18 (CK-18)/M65 and CK-18/M30 at Days 29, 57, 85, and 113

    Baseline was defined as the last measurement before first intake of study treatment on Day 1. Missing data were not imputed for the analysis.

    Time frame: Baseline (Day 1), Days 29, 57, 85, and 113

  4. Pharmacodynamics - Other Liver Markers: Change From Baseline in Ferritin at Days 29, 57, 85, and 113

    Baseline was defined as the last measurement before first intake of study treatment on Day 1. Missing data were not imputed for the analysis.

    Time frame: Baseline (Day 1), Days 29, 57, 85, and 113

  5. Pharmacodynamics - Other Liver Markers: Change From Baseline in Fibroblast Growth Factor 19 and Fibroblast Growth Factor 21 at Days 29, 57, 85, and 113

    Baseline was defined as the last measurement before first intake of study treatment on Day 1. Missing data were not imputed for the analysis.

    Time frame: Baseline (Day 1), Days 29, 57, 85, and 113

  6. Pharmacodynamics - Other Liver Markers: Change From Baseline in Hyaluronic Acid, Procollagen 3 N-Terminal Propeptide (PIIINP) and Tissue Inhibitor of Metalloproteinase 1 (TIMP1) at Days 29, 57, 85, and 113

    Baseline was defined as the last measurement before first intake of study treatment on Day 1. Missing data were not imputed for the analysis.

    Time frame: Baseline (Day 1), Days 29, 57, 85, and 113

  7. Pharmacodynamics - Other Liver Markers: Change From Baseline in Alpha-2 Macroglobulin at Days 29, 57, 85, and 113

    Baseline was defined as the last measurement before first intake of study treatment on Day 1. Missing data were not imputed for the analysis.

    Time frame: Baseline (Day 1), Days 29, 57, 85, and 113

  8. Pharmacodynamics - Glucose Homeostasis Markers: Change From Baseline in Fasting Plasma Glucose (FPG) at Days 15, 29, 57, 85, and 113

    Blood samples were taken after minimum 10 hours of fasting. Baseline was defined as the last measurement before first intake of study treatment on Day 1.

    Time frame: Baseline (Day 1), Days 15, 29, 57, 85, and 113

  9. Pharmacodynamics - Glucose Homeostasis Markers: Change From Baseline in Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) at Days 15, 29, 57, 85, and 113

    HOMA IR measures insulin resistance based on fasting glucose and insulin measurements: HOMA IR = fasting plasma insulin (micro international units per milliliter \[mcIU/mL\]) \* fasting plasma glucose (mmol/L) / 22.5. A higher value indicates a greater insulin resistance. Blood samples were taken after minimum 10 hours of fasting. Baseline was defined as the last measurement before first intake of study treatment on Day 1.

    Time frame: Baseline (Day 1), Days 15, 29, 57, 85, and 113

  10. Pharmacodynamics - Glucose Homeostasis Markers: Change From Baseline in Fasting Insulin at Days 15, 29, 57, 85, and 113

    Blood samples were taken after minimum 10 hours of fasting. Baseline was defined as the last measurement before first intake of study treatment on Day 1. Here, "mIU/L" was abbreviated as "milli-international unit per liter".

    Time frame: Baseline (Day 1), Days 15, 29, 57, 85, and 113

  11. Pharmacodynamics - Serum Lipid Parameters: Change From Baseline in Serum Total Cholesterol (TC) at Days 15, 29, 57, 85, and 113

    Baseline was defined as the last measurement before first intake of study treatment on Day 1.

    Time frame: Baseline (Day 1), Days 15, 29, 57, 85, and 113

  12. Pharmacodynamics - Serum Lipid Parameters: Change From Baseline in Serum Non High-density Lipoprotein Cholesterol (Non-HDL-C) at Days 15, 29, 57, 85, and 113

    Baseline was defined as the last measurement before first intake of study treatment on Day 1.

    Time frame: Baseline (Day 1), Days 15, 29, 57, 85, and 113

  13. Pharmacodynamics - Serum Lipid Parameters: Change From Baseline in Serum High-density Lipoprotein Cholesterol (HDL-C) at Days 15, 29, 57, 85, and 113

    Baseline was defined as the last measurement before first intake of study treatment on Day 1.

    Time frame: Baseline (Day 1), Days 15, 29, 57, 85, and 113

  14. Pharmacodynamics - Serum Lipid Parameters: Change From Baseline in Serum Low-density Lipoprotein (LDL-C) at Days 15, 29, 57, 85, and 113

    Baseline was defined as the last measurement before first intake of study treatment on Day 1.

    Time frame: Baseline (Day 1), Days 15, 29, 57, 85, and 113

  15. Pharmacodynamics - Serum Lipid Parameters: Change From Baseline in Serum Triglycerides at Days 15, 29, 57, 85, and 113

    Baseline was defined as the last measurement before first intake of study treatment on Day 1.

    Time frame: Baseline (Day 1), Days 15, 29, 57, 85, and 113

  16. Pharmacodynamics - Serum Lipid Parameters: Change From Baseline in Serum Calculated Very Low-density Lipoprotein Cholesterol (VLDL-C) at Days 15, 29, 57, 85, and 113

    Baseline was defined as the last measurement before first intake of study treatment on Day 1.

    Time frame: Baseline (Day 1), Days 15, 29, 57, 85, and 113

  17. Pharmacodynamics - Serum Lipid Parameters: Change From Baseline in Serum Apolipoprotein A-1 at Days 15, 29, 57, 85, and 113

    Baseline was defined as the last measurement before first intake of study treatment on Day 1.

    Time frame: Baseline (Day 1), Days 15, 29, 57, 85, and 113

  18. Pharmacodynamics - Serum Lipid Parameters: Change From Baseline in Serum Apolipoprotein B at Days 15, 29, 57, 85, and 113

    Baseline was defined as the last measurement before first intake of study treatment on Day 1.

    Time frame: Baseline (Day 1), Days 15, 29, 57, 85, and 113

  19. Pharmacodynamics - Change From Baseline in Body Weight at Days 15, 29, 57, 85, and 113

    Baseline was defined as the last measurement before first intake of study treatment on Day 1.

    Time frame: Baseline (Day 1), Days 15, 29, 57, 85, and 113

  20. Pharmacodynamics - Change From Baseline in Body Mass Index (BMI) Z-Score at Days 15, 29, 57, 85, and 113

    The BMI for a given age (in years) and gender (male) was converted to an exact z-score. Given a participant's age, sex, BMI, and an appropriate reference standard, a BMI Z-score was determined. BMI Z-score \>=85th percentile was considered as overweight. Z-score was a statistical measure to describe whether a mean was above or below the standard. A Z-score of 0 was equal to the mean and is considered normal. Negative numbers indicate values lower than the mean and positive numbers indicate values higher than the mean. Negative values are indicative of decrease in BMI (weight loss) and positive values are indicative of increase in BMI. Baseline was defined as the last measurement before first intake of study treatment on Day 1.

    Time frame: Baseline (Day 1), Days 15, 29, 57, 85, and 113

  21. Pharmacodynamics - Change From Baseline in Waist Circumference at Days 15, 29, 57, 85, and 113

    Waist circumference (in centimeters \[cm\]) was measured at the midpoint between the lower margin of the least palpable rib and the top of the iliac crest. Baseline was defined as the last measurement before first intake of study treatment on Day 1.

    Time frame: Baseline (Day 1), Days 15, 29, 57, 85, and 113

  22. Pharmacodynamics - Inflammatory Marker: Change From Baseline in Fibrinogen at Days 29, 57, 85, and 113

    Blood samples to assess fibrinogen levels were taken after minimum 10 hours of fasting. Baseline was defined as the last measurement before first intake of study treatment on Day 1.

    Time frame: Baseline (Day 1), Days 29, 57, 85, and 113

  23. Pharmacodynamics - Inflammatory Marker: Change From Baseline in Haptoglobin at Days 29, 57, 85, and 113

    Blood samples to assess Haptoglobin level were taken after minimum 10 hours of fasting. Baseline was defined as the last measurement before first intake of study treatment on Day 1.

    Time frame: Baseline (Day 1), Days 29, 57, 85, and 113

  24. Pharmacodynamics - Inflammatory Marker: Change From Baseline in Interleukin-6 at Days 29, 57, 85, and 113

    Blood samples to assess Interleukin-6 level were taken after minimum 10 hours of fasting. Baseline was defined as the last measurement before first intake of study treatment on Day 1.

    Time frame: Baseline (Day 1), Days 29, 57, 85, and 113

  25. Pharmacodynamics - Inflammatory Marker: Change From Baseline in Tumor Necrosis Factor Alpha at Days 29, 57, 85, and 113

    Blood samples to assess Necrosis Factor Alpha level were taken after minimum 10 hours of fasting. Baseline was defined as the last measurement before first intake of study treatment on Day 1.

    Time frame: Baseline (Day 1), Days 29, 57, 85, and 113

  26. Pharmacodynamics - Inflammatory Marker: Change From Baseline in Plasminogen Activator Inhibitor-1 at Days 29, 57, 85, and 113

    Blood samples to assess plasminogen activator inhibitor-1 level were taken after minimum 10 hours of fasting. Baseline was defined as the last measurement before first intake of study treatment on Day 1. Here, "IU/mL" was abbreviated as International units per milliliter.

    Time frame: Baseline (Day 1), Day 29, 57, 85, and 113

  27. Pharmacodynamics - Change From Baseline in Pediatric Quality of Life (PedsQL™) (Version 4.0) Generic Core Scales at Day 85

    The child, adolescent and parent/legal guardian PedsQL™ (Version 4.0) generic core scales was used to measure health-related quality of life (HRQOL). The response information was completed by the participant and by a parent/legal guardian individually. It consisted of 23 item questionnaire encompassing 4 core scale domains: Physical Functioning (8 items); Emotional Functioning (5 items); Social Functioning (5 items); and School Functioning (5 items). Items were scored on a 5 point Likert-type response scale: 0=never a problem to 1=almost never a problem; 2=sometimes a problem; 3=often a problem; and 4=almost always a problem). Once scored, items were reverse scored and linearly transformed to a 0-100 scale (0=100, 1=75, 2=50, 3=25, 4=0), where higher scores indicated better HRQOL. Total Scale Score was the sum of all the items over the number of items answered on all the Scales. Baseline was defined as the last measurement before first intake of study treatment on Day 1.

    Time frame: Baseline (Day 1), Day 85

  28. Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious TEAEs

    An adverse event (AE) was any untoward medical in a participant or clinical investigation patient administered a pharmaceutical (investigational) product and which does not necessarily have to have a causal relationship with this treatment. A Serious adverse event (SAE) was any untoward medical occurrence that at any dose: resulted in death, was life-threatening, required inpatient hospitalization/prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, was another medically important condition. TEAEs were defined as AEs that started prior to first study drug dose and that worsened after, and the AEs that started on or after first study drug dose. TEAEs: Serious and non-serious AEs.

    Time frame: From Screening visit (signature of informed consent) up to last dose of study drug + 30 days (i.e., up to Day 113)

  29. Number of Participants With Clinically Significant Abnormalities in 12-lead Electrocardiogram (ECG) Measurement

    ECG measurements were taken with the participants in resting position for at least 10 minutes. The investigator determined whether abnormal assessment results were clinically significant or not. The number of participants with abnormal clinically significant ECG findings were reported. Baseline was defined as the last measurement before first intake of study treatment on Day 1.

    Time frame: Baseline (Day 1), Day 85

  30. Number of Participants With Abnormal Clinical Chemistry Parameters

    Fasting blood samples (collected after 10 hours fasting) were used to assess the following clinical chemistry parameters: creatinine, glomerular filtration rate, creatinine clearance, total proteins, albumin, electrolytes (sodium, potassium, chloride, calcium), uric acid, urea nitrogen, urea, creatine phosphokinase (CPK), AST, ALT, GGT, ALP, total and conjugated bilirubin, high sensitivity C-reactive protein, fasting plasma glucose, fasting insulin, HOMA-IR, fructosamine, C-peptide, free fatty acids, glycated hemoglobin A1c, cystatin C. Abnormal clinical chemistry values were classified based on reference range: lower limit of normality (LLN); normal (\>= LLN and \<= upper limit of normality \[ULN\]); \> ULN and \<3 ULN; \>=3 ULN and \<5 ULN and \>=5 ULN. Only the parameters for which at least one value of abnormality were reported and presented in this outcome measure.

    Time frame: At Day 85 (i.e., end of treatment)

  31. Number of Participants With Abnormal Hematology and Coagulation Parameters

    Fasting blood samples (collected after 10 hours fasting) were used to assess the following hematology and coagulation parameters: hemoglobin, hematocrit, red blood cells (RBC), white blood cells (WBC), neutrophils, eosinophils, basophils, lymphocytes, monocytes, platelets, prothrombin time (PT) and international normalized ratio (INR). Hematology and coagulation values were classified based on the reference range: LLN; normal (\>= LLN and \<= ULN); \> ULN and \<3 ULN; \>=3 ULN and \<5 ULN and \>=5 ULN.

    Time frame: At Day 85 (i.e., end of treatment)

  32. Number of Participants With Abnormal Urinalysis Parameters

    Blood samples were collected to assess the following urinalysis parameters: alpha-1 macroglobulin, N-acetyl glucosamide, neutrophil gelatinase-associated lipocalin, albumin, and creatinine. Abnormal urinalysis values were classified based on the reference range: LLN; normal (\>= LLN and \<= ULN); \> ULN and \<3 ULN; \>=3 ULN and \<5 ULN and \>=5 ULN.

    Time frame: At Day 85 (i.e., end of treatment)

  33. Number of Participants With Abnormal Vital Signs

    Vital signs were taken before any invasive procedures. Following vital signs were assessed: systolic blood pressure, diastolic blood pressure, heart rate. Abnormal vita signs was defined as any abnormal findings in the vital sign parameters and were categorized as 'abnormal, not clinically significant (NCS)' and 'abnormal, clinically significant (CS)'.

    Time frame: At Day 85 (i.e., end of treatment)

  34. Number of Participants With Clinically Significant Abnormalities in Physical Examination at Baseline, Days 15, 29, 57, 85, and 113

    Physical examination findings were collected according to pre-defined body systems: general appearance; skin; eyes; ears; nose; throat; neck and thyroid; lungs; heart; upper/lower extremities; lymph nodes; abdomen; musculoskeletal system; basic neurological assessment. Additional systems were evaluated as needed. Clinical significance was defined as any variation in assessment results that had medical relevance resulting in an alteration in medical care. Participants with at least one clinically significant abnormality in physical examination were reported and presented in this outcome measure. Baseline was defined as the last measurement before first intake of study treatment on Day 1.

    Time frame: Baseline (Day 1), Days 15, 29, 57, 85, and 113

07

Results

Posted Oct 28, 2021
Limitations and caveats
Due to lack of efficacy (but not due to safety) in a Phase 3 trial of elafibranor in adult participants with NASH and fibrosis, this study in pediatric NASH was prematurely terminated. Therefore, participants \>=12 to \<=17 years of age were only involved in this study.

Participant flow

The study was conducted at 2 centers in the United Sates from 25 June 2019 and 16 June 2020. A total of 27 participants were screened, of which 10 participants were enrolled and randomized (1:1 ratio) to receive elafibranor 80 milligrams (mg)/120 mg sequentially. A total of 17 participants failed screening mainly due to not meeting eligibility criteria.

Participant flow — Overall Study
MilestoneElafibranor 80 mgElafibranor 120 mg
Started55
Completed55
Not completed00

Outcome measures

PrimaryPharmacokinetics (PK): Maximum Observed Plasma Concentration (Cmax) of Elafibranor and Its Active Metabolite (GFT1007)

Cmax was defined as maximum observed plasma concentration.

Time frame:
Day 1: at pre-dose; Day 29: at pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8 hours post dose; Day 30 and 85: at 24 hours after previous day dose administration
Reported as:
Mean · nanograms per milliliter (ng/mL)
Pharmacokinetics (PK): Maximum Observed Plasma Concentration (Cmax) of Elafibranor and Its Active Metabolite (GFT1007)
nanograms per milliliter (ng/mL)Elafibranor 80 mgElafibranor 120 mg
Elafibranor385.216 ± 218.646658.054 ± 403.201
GFT10072367.620 ± 1088.1232875.280 ± 1443.324
PrimaryPharmacokinetics: Time to Maximum Observed Plasma Concentration (Tmax) of Elafibranor and Active Metabolite (GFT1007)

Tmax was defined as time to reach maximum observed plasma concentration.

Time frame:
Day 1: at pre-dose; Day 29: at pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8 hours post dose; Day 30 and 85: at 24 hours after previous day dose administration
Reported as:
Median · hours
Pharmacokinetics: Time to Maximum Observed Plasma Concentration (Tmax) of Elafibranor and Active Metabolite (GFT1007)
hoursElafibranor 80 mgElafibranor 120 mg
Elafibranor1.50 (0.52 to 2.00)1.00 (0.98 to 1.50)
GFT10072.00 (1.50 to 2.00)1.50 (1.00 to 1.50)
PrimaryPharmacokinetics: Area Under The Plasma Concentration-time Curve From 0 to 24 Hours (AUC0-24) of Elafibranor and Active Metabolite (GFT1007)

AUC0-24 defined as the area under the plasma concentration versus time curve of the study drug from time 0 to 24 hours.

Time frame:
Day 1: at pre-dose; Day 29: at pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8 hours post dose; Day 30 and 85: at 24 hours after previous day dose administration
Reported as:
Mean · nanograms*hour per milliliter
Pharmacokinetics: Area Under The Plasma Concentration-time Curve From 0 to 24 Hours (AUC0-24) of Elafibranor and Active Metabolite (GFT1007)
nanograms*hour per milliliterElafibranor 80 mgElafibranor 120 mg
Elafibranor973.301 ± 311.8031457.728 ± 724.018
GFT100710011.405 ± 3575.22010532.930 ± 3257.220
PrimaryPharmacokinetics: Terminal Elimination Half-life ( t½) of Elafibranor and Active Metabolite (GFT1007)

Plasma t1/2 was defined as the time taken by drug to reduce to half of its initial plasma concentration.

Time frame:
Day 1: at pre-dose; Day 29: at pre-dose, 0.5, 1, 1.5, 2, 4, 6, 8 hours post dose; Day 30 and 85: at 24 hours after previous day dose administration
Reported as:
Mean · hours
Pharmacokinetics: Terminal Elimination Half-life ( t½) of Elafibranor and Active Metabolite (GFT1007)
hoursElafibranor 80 mgElafibranor 120 mg
Elafibranor34.170 ± NA37.620 ± 15.473
GFT10079.572 ± 5.5926.682 ± 1.120
PrimaryPharmacokinetics: Plasma Trough Concentrations (Ctrough) of Elafibranor and Active Metabolite (GFT1007)

Ctrough was defined as the plasma concentration of study drug observed just before treatment administration during repeated dosing.

Time frame:
Pre-dose on Day 1 and 29
Reported as:
Mean · ng/mL
Pharmacokinetics: Plasma Trough Concentrations (Ctrough) of Elafibranor and Active Metabolite (GFT1007)
ng/mLElafibranor 80 mgElafibranor 120 mg
Elafibranor14.904 ± 3.51629.035 ± 15.087
GFT100797.771 ± 49.63655.243 ± 27.769
SecondaryPharmacodynamics (PD) - Liver Markers: Change From Baseline in Serum Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Gamma-glutamyl Transferase (GGT), and Alkaline Phosphatase (ALP) at Days 15, 29, 57, 85, and 113

Baseline was defined as the last measurement before first intake of study treatment on Day 1. Missing data were not imputed for the analysis. Normal range at screening: AST: 0 - 39 international units per liter (IU/L), ALT: 5 - 30 IU/L, GGT: 2 - 24 IU/L, and ALP: 74 - 390 IU/L.

Time frame:
Baseline (Day 1), Days 15, 29, 57, 85, and 113
Reported as:
Mean · IU/L
Pharmacodynamics (PD) - Liver Markers: Change From Baseline in Serum Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Gamma-glutamyl Transferase (GGT), and Alkaline Phosphatase (ALP) at Days 15, 29, 57, 85, and 113
IU/LElafibranor 80 mgElafibranor 120 mg
ALT: Day 154.2 ± 21.7-13.8 ± 25.0
ALT: Day 29-0.2 ± 35.9-27.6 ± 18.4
ALT: Day 570.2 ± 27.3-30.8 ± 16.5
ALT: Day 8517.8 ± 56.6-34.6 ± 25.6
ALT: Day 11337.3 ± 46.9-28.0 ± 22.2
AST: Day 154.0 ± 16.00.8 ± 9.5
AST: Day 294.0 ± 16.3-4.0 ± 9.5
AST: Day 571.0 ± 6.1-5.8 ± 4.1
AST: Day 857.4 ± 15.3-8.2 ± 8.3
AST: Day 1139.3 ± 8.4-7.8 ± 8.7
GGT: Day 15-9.2 ± 6.8-8.8 ± 4.4
GGT: Day 29-15.6 ± 9.9-16.0 ± 5.9
GGT: Day 57-1.0 ± 20.7-15.6 ± 9.1
GGT: Day 8511.2 ± 39.1-16.2 ± 9.9
GGT: Day 11345.3 ± 43.8-9.5 ± 6.6
ALP: Day 15-4.6 ± 23.1-18.0 ± 11.2
ALP: Day 29-24.8 ± 28.4-14.6 ± 8.1
ALP: Day 57-28.2 ± 36.5-18.4 ± 8.2
ALP: Day 85-32.6 ± 51.5-25.0 ± 12.4
ALP: Day 113-7.8 ± 45.4-16.8 ± 10.2
SecondaryPharmacodynamics - Other Liver Markers: Change From Baseline in Adiponectin at Days 29, 57, 85, and 113

Baseline was defined as the last measurement before first intake of study treatment on Day 1. Missing data were not imputed for the analysis.

Time frame:
Baseline (Day 1), Days 29, 57, 85, and 113
Reported as:
Mean · micrograms per milliliter (mcg/mL)
Pharmacodynamics - Other Liver Markers: Change From Baseline in Adiponectin at Days 29, 57, 85, and 113
micrograms per milliliter (mcg/mL)Elafibranor 80 mgElafibranor 120 mg
Day 290.2410 ± 0.37290.2112 ± 1.0304
Day 570.5780 ± 1.0530-0.2752 ± 1.0022
Day 850.3372 ± 1.4844-0.0590 ± 1.0476
Day 113-0.4663 ± 0.89720.0322 ± 1.0588
SecondaryPharmacodynamics - Other Liver Markers: Change From Baseline in Cytokeratin 18 (CK-18)/M65 and CK-18/M30 at Days 29, 57, 85, and 113

Baseline was defined as the last measurement before first intake of study treatment on Day 1. Missing data were not imputed for the analysis.

Time frame:
Baseline (Day 1), Days 29, 57, 85, and 113
Reported as:
Mean · IU/L
Pharmacodynamics - Other Liver Markers: Change From Baseline in Cytokeratin 18 (CK-18)/M65 and CK-18/M30 at Days 29, 57, 85, and 113
IU/LElafibranor 80 mgElafibranor 120 mg
CK-18/M65: Day 2939.412 ± 346.370-70.902 ± 121.905
CK-18/M65: Day 57-30.302 ± 326.632-60.578 ± 186.165
CK-18/M65: Day 85-2.320 ± 231.775-122.070 ± 265.059
CK-18/M65: Day 113235.205 ± 290.846-188.638 ± 244.324
CK-18/M30: Day 29-24.282 ± 374.146-68.896 ± 96.850
CK-18/M30: Day 577.530 ± 445.509-20.074 ± 219.782
CK-18/M30: Day 85-54.988 ± 315.261-81.492 ± 271.506
CK-18/M30: Day 113146.412 ± 273.673-170.793 ± 235.722
SecondaryPharmacodynamics - Other Liver Markers: Change From Baseline in Ferritin at Days 29, 57, 85, and 113

Baseline was defined as the last measurement before first intake of study treatment on Day 1. Missing data were not imputed for the analysis.

Time frame:
Baseline (Day 1), Days 29, 57, 85, and 113
Reported as:
Mean · micrograms per liter (mcg/L)
Pharmacodynamics - Other Liver Markers: Change From Baseline in Ferritin at Days 29, 57, 85, and 113
micrograms per liter (mcg/L)Elafibranor 80 mgElafibranor 120 mg
Day 296.4 ± 12.010.8 ± 25.9
Day 5719.4 ± 23.53.6 ± 15.6
Day 8511.8 ± 16.6-4.0 ± 2.4
Day 1136.0 ± 5.7-12.8 ± 11.1
SecondaryPharmacodynamics - Other Liver Markers: Change From Baseline in Fibroblast Growth Factor 19 and Fibroblast Growth Factor 21 at Days 29, 57, 85, and 113

Baseline was defined as the last measurement before first intake of study treatment on Day 1. Missing data were not imputed for the analysis.

Time frame:
Baseline (Day 1), Days 29, 57, 85, and 113
Reported as:
Mean · picograms per milliliter (pg/mL)
Pharmacodynamics - Other Liver Markers: Change From Baseline in Fibroblast Growth Factor 19 and Fibroblast Growth Factor 21 at Days 29, 57, 85, and 113
picograms per milliliter (pg/mL)Elafibranor 80 mgElafibranor 120 mg
Fibroblast Growth Factor 19: Day 29-24.4 ± 80.6-42.8 ± 78.0
Fibroblast Growth Factor 19: Day 57-10.4 ± 51.2-18.8 ± 85.3
Fibroblast Growth Factor 19: Day 8528.4 ± 77.5-13.0 ± 100.6
Fibroblast Growth Factor 19: Day 113-7.8 ± 61.3-19.8 ± 35.3
Fibroblast Growth Factor 21: Day 299.98 ± 91.38128.84 ± 171.50
Fibroblast Growth Factor 21: Day 57-36.36 ± 188.91195.94 ± 315.73
Fibroblast Growth Factor 21: Day 85120.68 ± 191.6281.56 ± 130.68
Fibroblast Growth Factor 21: Day 1133.50 ± 291.4156.35 ± 87.53
SecondaryPharmacodynamics - Other Liver Markers: Change From Baseline in Hyaluronic Acid, Procollagen 3 N-Terminal Propeptide (PIIINP) and Tissue Inhibitor of Metalloproteinase 1 (TIMP1) at Days 29, 57, 85, and 113

Baseline was defined as the last measurement before first intake of study treatment on Day 1. Missing data were not imputed for the analysis.

Time frame:
Baseline (Day 1), Days 29, 57, 85, and 113
Reported as:
Mean · nanograms per milliliter (ng/mL)
Pharmacodynamics - Other Liver Markers: Change From Baseline in Hyaluronic Acid, Procollagen 3 N-Terminal Propeptide (PIIINP) and Tissue Inhibitor of Metalloproteinase 1 (TIMP1) at Days 29, 57, 85, and 113
nanograms per milliliter (ng/mL)Elafibranor 80 mgElafibranor 120 mg
Hyaluronic Acid: Day 29-2.958 ± 11.689-8.800 ± 10.991
Hyaluronic Acid: Day 57-0.272 ± 9.228-3.654 ± 10.528
Hyaluronic Acid: Day 854.408 ± 16.612-3.518 ± 15.130
Hyaluronic Acid: Day 1131.592 ± 16.445-0.422 ± 19.347
Procollagen 3 N-Terminal Propeptide: Day 29-3.018 ± 14.079-2.878 ± 3.138
Procollagen 3 N-Terminal Propeptide: Day 571.730 ± 6.928-2.762 ± 3.242
Procollagen 3 N-Terminal Propeptide: Day 85-1.710 ± 6.730-0.470 ± 5.270
Procollagen 3 N-Terminal Propeptide: Day 113-7.015 ± 11.902-0.530 ± 3.701
Tissue Inhibitor of Metalloproteinase 1: Day 29-3.56 ± 25.38-8.52 ± 8.98
Tissue Inhibitor of Metalloproteinase 1: Day 572.80 ± 15.35-26.20 ± 32.29
Tissue Inhibitor of Metalloproteinase 1: Day 8516.02 ± 24.84-26.26 ± 25.43
Tissue Inhibitor of Metalloproteinase 1: Day 11310.92 ± 21.58-31.35 ± 37.95
SecondaryPharmacodynamics - Other Liver Markers: Change From Baseline in Alpha-2 Macroglobulin at Days 29, 57, 85, and 113

Baseline was defined as the last measurement before first intake of study treatment on Day 1. Missing data were not imputed for the analysis.

Time frame:
Baseline (Day 1), Days 29, 57, 85, and 113
Reported as:
Mean · gram per liter (g/L)
Pharmacodynamics - Other Liver Markers: Change From Baseline in Alpha-2 Macroglobulin at Days 29, 57, 85, and 113
gram per liter (g/L)Elafibranor 80 mgElafibranor 120 mg
Day 29-0.098 ± 0.254-0.282 ± 0.133
Day 570.124 ± 0.213-0.118 ± 0.064
Day 85-0.030 ± 0.328-0.204 ± 0.129
Day 113-0.105 ± 0.319-0.037 ± 0.157
SecondaryPharmacodynamics - Glucose Homeostasis Markers: Change From Baseline in Fasting Plasma Glucose (FPG) at Days 15, 29, 57, 85, and 113

Blood samples were taken after minimum 10 hours of fasting. Baseline was defined as the last measurement before first intake of study treatment on Day 1.

Time frame:
Baseline (Day 1), Days 15, 29, 57, 85, and 113
Reported as:
Mean · millimoles per liter (mmol/L)
Pharmacodynamics - Glucose Homeostasis Markers: Change From Baseline in Fasting Plasma Glucose (FPG) at Days 15, 29, 57, 85, and 113
millimoles per liter (mmol/L)Elafibranor 80 mgElafibranor 120 mg
Day 150.22 ± 0.340.22 ± 0.28
Day 290.34 ± 0.610.12 ± 0.47
Day 570.18 ± 0.580.10 ± 0.24
Day 850.28 ± 0.630.08 ± 0.45
Day 1130.58 ± 0.520.17 ± 0.35
SecondaryPharmacodynamics - Glucose Homeostasis Markers: Change From Baseline in Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) at Days 15, 29, 57, 85, and 113

HOMA IR measures insulin resistance based on fasting glucose and insulin measurements: HOMA IR = fasting plasma insulin (micro international units per milliliter \[mcIU/mL\]) \* fasting plasma glucose (mmol/L) / 22.5. A higher value indicates a greater insulin resistance. Blood samples were taken after minimum 10 hours of fasting. Baseline was defined as the last measurement before first intake of study treatment on Day 1.

Time frame:
Baseline (Day 1), Days 15, 29, 57, 85, and 113
Reported as:
Mean · Insulin resistance
Pharmacodynamics - Glucose Homeostasis Markers: Change From Baseline in Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) at Days 15, 29, 57, 85, and 113
Insulin resistanceElafibranor 80 mgElafibranor 120 mg
Day 1510.720 ± 17.650-3.640 ± 5.215
Day 2916.498 ± 43.577-4.028 ± 6.512
Day 574.958 ± 15.472-5.448 ± 3.572
Day 853.742 ± 6.853-1.968 ± 7.112
Day 11313.323 ± 22.795-4.623 ± 6.883
SecondaryPharmacodynamics - Glucose Homeostasis Markers: Change From Baseline in Fasting Insulin at Days 15, 29, 57, 85, and 113

Blood samples were taken after minimum 10 hours of fasting. Baseline was defined as the last measurement before first intake of study treatment on Day 1. Here, "mIU/L" was abbreviated as "milli-international unit per liter".

Time frame:
Baseline (Day 1), Days 15, 29, 57, 85, and 113
Reported as:
Mean · mIU/L
Pharmacodynamics - Glucose Homeostasis Markers: Change From Baseline in Fasting Insulin at Days 15, 29, 57, 85, and 113
mIU/LElafibranor 80 mgElafibranor 120 mg
Day 1530.88 ± 53.53-15.66 ± 20.92
Day 2940.12 ± 116.20-16.76 ± 24.12
Day 5712.42 ± 41.76-23.10 ± 12.58
Day 859.70 ± 15.49-7.48 ± 26.76
Day 11334.15 ± 58.20-19.57 ± 25.56
SecondaryPharmacodynamics - Serum Lipid Parameters: Change From Baseline in Serum Total Cholesterol (TC) at Days 15, 29, 57, 85, and 113

Baseline was defined as the last measurement before first intake of study treatment on Day 1.

Time frame:
Baseline (Day 1), Days 15, 29, 57, 85, and 113
Reported as:
Mean · mmol/L
Pharmacodynamics - Serum Lipid Parameters: Change From Baseline in Serum Total Cholesterol (TC) at Days 15, 29, 57, 85, and 113
mmol/LElafibranor 80 mgElafibranor 120 mg
Day 15-0.070 ± 0.440-0.328 ± 0.230
Day 29-0.356 ± 0.252-0.288 ± 0.347
Day 570.380 ± 0.565-0.286 ± 0.129
Day 850.298 ± 0.836-0.274 ± 0.306
Day 1130.665 ± 0.9190.105 ± 0.270
SecondaryPharmacodynamics - Serum Lipid Parameters: Change From Baseline in Serum Non High-density Lipoprotein Cholesterol (Non-HDL-C) at Days 15, 29, 57, 85, and 113

Baseline was defined as the last measurement before first intake of study treatment on Day 1.

Time frame:
Baseline (Day 1), Days 15, 29, 57, 85, and 113
Reported as:
Mean · mmol/L
Pharmacodynamics - Serum Lipid Parameters: Change From Baseline in Serum Non High-density Lipoprotein Cholesterol (Non-HDL-C) at Days 15, 29, 57, 85, and 113
mmol/LElafibranor 80 mgElafibranor 120 mg
Day 15-0.134 ± 0.414-0.348 ± 0.163
Day 29-0.324 ± 0.196-0.316 ± 0.432
Day 570.368 ± 0.340-0.316 ± 0.194
Day 850.156 ± 0.615-0.420 ± 0.290
Day 1130.605 ± 0.714-0.038 ± 0.229
SecondaryPharmacodynamics - Serum Lipid Parameters: Change From Baseline in Serum High-density Lipoprotein Cholesterol (HDL-C) at Days 15, 29, 57, 85, and 113

Baseline was defined as the last measurement before first intake of study treatment on Day 1.

Time frame:
Baseline (Day 1), Days 15, 29, 57, 85, and 113
Reported as:
Mean · mmol/L
Pharmacodynamics - Serum Lipid Parameters: Change From Baseline in Serum High-density Lipoprotein Cholesterol (HDL-C) at Days 15, 29, 57, 85, and 113
mmol/LElafibranor 80 mgElafibranor 120 mg
Day 150.060 ± 0.0680.020 ± 0.223
Day 29-0.032 ± 0.1240.032 ± 0.137
Day 570.008 ± 0.2280.030 ± 0.168
Day 850.138 ± 0.2780.150 ± 0.191
Day 1130.065 ± 0.2590.150 ± 0.047
SecondaryPharmacodynamics - Serum Lipid Parameters: Change From Baseline in Serum Low-density Lipoprotein (LDL-C) at Days 15, 29, 57, 85, and 113

Baseline was defined as the last measurement before first intake of study treatment on Day 1.

Time frame:
Baseline (Day 1), Days 15, 29, 57, 85, and 113
Reported as:
Mean · mmol/L
Pharmacodynamics - Serum Lipid Parameters: Change From Baseline in Serum Low-density Lipoprotein (LDL-C) at Days 15, 29, 57, 85, and 113
mmol/LElafibranor 80 mgElafibranor 120 mg
Day 15-0.224 ± 0.365-0.084 ± 0.213
Day 29-0.344 ± 0.184-0.076 ± 0.355
Day 570.314 ± 0.355-0.038 ± 0.078
Day 850.080 ± 0.686-0.184 ± 0.223
Day 1130.385 ± 0.6910.108 ± 0.134
SecondaryPharmacodynamics - Serum Lipid Parameters: Change From Baseline in Serum Triglycerides at Days 15, 29, 57, 85, and 113

Baseline was defined as the last measurement before first intake of study treatment on Day 1.

Time frame:
Baseline (Day 1), Days 15, 29, 57, 85, and 113
Reported as:
Mean · mmol/L
Pharmacodynamics - Serum Lipid Parameters: Change From Baseline in Serum Triglycerides at Days 15, 29, 57, 85, and 113
mmol/LElafibranor 80 mgElafibranor 120 mg
Day 150.200 ± 0.363-0.576 ± 0.442
Day 290.042 ± 0.214-0.530 ± 0.385
Day 570.124 ± 0.326-0.606 ± 0.384
Day 850.170 ± 0.389-0.532 ± 0.399
Day 1130.485 ± 0.918-0.315 ± 0.353
SecondaryPharmacodynamics - Serum Lipid Parameters: Change From Baseline in Serum Calculated Very Low-density Lipoprotein Cholesterol (VLDL-C) at Days 15, 29, 57, 85, and 113

Baseline was defined as the last measurement before first intake of study treatment on Day 1.

Time frame:
Baseline (Day 1), Days 15, 29, 57, 85, and 113
Reported as:
Mean · mmol/L
Pharmacodynamics - Serum Lipid Parameters: Change From Baseline in Serum Calculated Very Low-density Lipoprotein Cholesterol (VLDL-C) at Days 15, 29, 57, 85, and 113
mmol/LElafibranor 80 mgElafibranor 120 mg
Day 150.086 ± 0.172-0.270 ± 0.200
Day 290.018 ± 0.103-0.244 ± 0.168
Day 570.052 ± 0.140-0.282 ± 0.176
Day 850.072 ± 0.168-0.240 ± 0.176
Day 1130.215 ± 0.419-0.153 ± 0.156
SecondaryPharmacodynamics - Serum Lipid Parameters: Change From Baseline in Serum Apolipoprotein A-1 at Days 15, 29, 57, 85, and 113

Baseline was defined as the last measurement before first intake of study treatment on Day 1.

Time frame:
Baseline (Day 1), Days 15, 29, 57, 85, and 113
Reported as:
Mean · grams per liter (g/L)
Pharmacodynamics - Serum Lipid Parameters: Change From Baseline in Serum Apolipoprotein A-1 at Days 15, 29, 57, 85, and 113
grams per liter (g/L)Elafibranor 80 mgElafibranor 120 mg
Day 150.112 ± 0.129-0.058 ± 0.149
Day 290.012 ± 0.139-0.058 ± 0.144
Day 570.108 ± 0.211-0.060 ± 0.176
Day 850.128 ± 0.2680.016 ± 0.160
Day 1130.103 ± 0.3130.048 ± 0.060
SecondaryPharmacodynamics - Serum Lipid Parameters: Change From Baseline in Serum Apolipoprotein B at Days 15, 29, 57, 85, and 113

Baseline was defined as the last measurement before first intake of study treatment on Day 1.

Time frame:
Baseline (Day 1), Days 15, 29, 57, 85, and 113
Reported as:
Mean · g/L
Pharmacodynamics - Serum Lipid Parameters: Change From Baseline in Serum Apolipoprotein B at Days 15, 29, 57, 85, and 113
g/LElafibranor 80 mgElafibranor 120 mg
Day 15-0.058 ± 0.064-0.082 ± 0.074
Day 29-0.098 ± 0.081-0.078 ± 0.097
Day 570.066 ± 0.092-0.062 ± 0.086
Day 850.020 ± 0.189-0.036 ± 0.090
Day 1130.117 ± 0.209-0.005 ± 0.135
SecondaryPharmacodynamics - Change From Baseline in Body Weight at Days 15, 29, 57, 85, and 113

Baseline was defined as the last measurement before first intake of study treatment on Day 1.

Time frame:
Baseline (Day 1), Days 15, 29, 57, 85, and 113
Reported as:
Mean · kilograms (kg)
Pharmacodynamics - Change From Baseline in Body Weight at Days 15, 29, 57, 85, and 113
kilograms (kg)Elafibranor 80 mgElafibranor 120 mg
Day 15-0.08 ± 3.03-0.92 ± 1.70
Day 29-0.32 ± 4.54-0.98 ± 2.06
Day 570.73 ± 5.18-0.68 ± 3.27
Day 851.54 ± 5.420.24 ± 4.07
Day 1134.40 ± 3.050.73 ± 4.63
SecondaryPharmacodynamics - Change From Baseline in Body Mass Index (BMI) Z-Score at Days 15, 29, 57, 85, and 113

The BMI for a given age (in years) and gender (male) was converted to an exact z-score. Given a participant's age, sex, BMI, and an appropriate reference standard, a BMI Z-score was determined. BMI Z-score \>=85th percentile was considered as overweight. Z-score was a statistical measure to describe whether a mean was above or below the standard. A Z-score of 0 was equal to the mean and is considered normal. Negative numbers indicate values lower than the mean and positive numbers indicate values higher than the mean. Negative values are indicative of decrease in BMI (weight loss) and positive values are indicative of increase in BMI. Baseline was defined as the last measurement before first intake of study treatment on Day 1.

Time frame:
Baseline (Day 1), Days 15, 29, 57, 85, and 113
Reported as:
Mean · Z-Score
Pharmacodynamics - Change From Baseline in Body Mass Index (BMI) Z-Score at Days 15, 29, 57, 85, and 113
Z-ScoreElafibranor 80 mgElafibranor 120 mg
Day 15-0.064 ± 0.146-0.054 ± 0.095
Day 29-0.091 ± 0.247-0.054 ± 0.110
Day 57-0.108 ± 0.284-0.058 ± 0.162
Day 85-0.074 ± 0.290-0.026 ± 0.197
Day 1130.068 ± 0.1160.022 ± 0.247
SecondaryPharmacodynamics - Change From Baseline in Waist Circumference at Days 15, 29, 57, 85, and 113

Waist circumference (in centimeters \[cm\]) was measured at the midpoint between the lower margin of the least palpable rib and the top of the iliac crest. Baseline was defined as the last measurement before first intake of study treatment on Day 1.

Time frame:
Baseline (Day 1), Days 15, 29, 57, 85, and 113
Reported as:
Mean · cm
Pharmacodynamics - Change From Baseline in Waist Circumference at Days 15, 29, 57, 85, and 113
cmElafibranor 80 mgElafibranor 120 mg
Day 15-1.056 ± 2.953-0.998 ± 2.961
Day 29-0.656 ± 3.654-2.010 ± 2.625
Day 57-0.316 ± 3.520-2.054 ± 4.106
Day 850.252 ± 3.379-1.346 ± 3.894
Day 1131.625 ± 2.394-0.580 ± 4.099
SecondaryPharmacodynamics - Inflammatory Marker: Change From Baseline in Fibrinogen at Days 29, 57, 85, and 113

Blood samples to assess fibrinogen levels were taken after minimum 10 hours of fasting. Baseline was defined as the last measurement before first intake of study treatment on Day 1.

Time frame:
Baseline (Day 1), Days 29, 57, 85, and 113
Reported as:
Mean · micromoles per liter (mcmol/L)
Pharmacodynamics - Inflammatory Marker: Change From Baseline in Fibrinogen at Days 29, 57, 85, and 113
micromoles per liter (mcmol/L)Elafibranor 80 mgElafibranor 120 mg
Day 29-1.450 ± 1.265-2.474 ± 1.418
Day 57-0.524 ± 1.309-2.220 ± 0.756
Day 85-1.340 ± 1.492-1.748 ± 1.000
Day 113-0.295 ± 1.936-1.150 ± 1.841
SecondaryPharmacodynamics - Inflammatory Marker: Change From Baseline in Haptoglobin at Days 29, 57, 85, and 113

Blood samples to assess Haptoglobin level were taken after minimum 10 hours of fasting. Baseline was defined as the last measurement before first intake of study treatment on Day 1.

Time frame:
Baseline (Day 1), Days 29, 57, 85, and 113
Reported as:
Mean · g/L
Pharmacodynamics - Inflammatory Marker: Change From Baseline in Haptoglobin at Days 29, 57, 85, and 113
g/LElafibranor 80 mgElafibranor 120 mg
Day 29-0.086 ± 0.102-0.350 ± 0.244
Day 570.068 ± 0.118-0.300 ± 0.209
Day 850.066 ± 0.077-0.298 ± 0.236
Day 1130.178 ± 0.208-0.058 ± 0.081
SecondaryPharmacodynamics - Inflammatory Marker: Change From Baseline in Interleukin-6 at Days 29, 57, 85, and 113

Blood samples to assess Interleukin-6 level were taken after minimum 10 hours of fasting. Baseline was defined as the last measurement before first intake of study treatment on Day 1.

Time frame:
Baseline (Day 1), Days 29, 57, 85, and 113
Reported as:
Mean · picograms per milliliter (pg/mL)
Pharmacodynamics - Inflammatory Marker: Change From Baseline in Interleukin-6 at Days 29, 57, 85, and 113
picograms per milliliter (pg/mL)Elafibranor 80 mgElafibranor 120 mg
Day 290.036 ± 0.0800.142 ± 0.751
Day 570.100 ± 0.224-0.092 ± 1.096
Day 850.142 ± 0.2430.062 ± 0.809
Day 1130.143 ± 0.2850.078 ± 0.534
SecondaryPharmacodynamics - Inflammatory Marker: Change From Baseline in Tumor Necrosis Factor Alpha at Days 29, 57, 85, and 113

Blood samples to assess Necrosis Factor Alpha level were taken after minimum 10 hours of fasting. Baseline was defined as the last measurement before first intake of study treatment on Day 1.

Time frame:
Baseline (Day 1), Days 29, 57, 85, and 113
Reported as:
Mean · pg/mL
Pharmacodynamics - Inflammatory Marker: Change From Baseline in Tumor Necrosis Factor Alpha at Days 29, 57, 85, and 113
pg/mLElafibranor 80 mgElafibranor 120 mg
Day 29-0.134 ± 0.437-0.460 ± 0.857
Day 570.068 ± 0.388-0.270 ± 0.651
Day 85-0.068 ± 0.416-0.622 ± 0.939
Day 1130.163 ± 0.534-0.445 ± 0.988
SecondaryPharmacodynamics - Inflammatory Marker: Change From Baseline in Plasminogen Activator Inhibitor-1 at Days 29, 57, 85, and 113

Blood samples to assess plasminogen activator inhibitor-1 level were taken after minimum 10 hours of fasting. Baseline was defined as the last measurement before first intake of study treatment on Day 1. Here, "IU/mL" was abbreviated as International units per milliliter.

Time frame:
Baseline (Day 1), Day 29, 57, 85, and 113
Reported as:
Mean · IU/mL
Pharmacodynamics - Inflammatory Marker: Change From Baseline in Plasminogen Activator Inhibitor-1 at Days 29, 57, 85, and 113
IU/mLElafibranor 80 mgElafibranor 120 mg
Day 29-8.95 ± 14.19-1.40 ± 10.33
Day 579.68 ± 32.872.46 ± 15.03
Day 85-2.43 ± 7.572.62 ± 23.77
Day 1135.75 ± 26.715.40 ± 5.42
SecondaryPharmacodynamics - Change From Baseline in Pediatric Quality of Life (PedsQL™) (Version 4.0) Generic Core Scales at Day 85

The child, adolescent and parent/legal guardian PedsQL™ (Version 4.0) generic core scales was used to measure health-related quality of life (HRQOL). The response information was completed by the participant and by a parent/legal guardian individually. It consisted of 23 item questionnaire encompassing 4 core scale domains: Physical Functioning (8 items); Emotional Functioning (5 items); Social Functioning (5 items); and School Functioning (5 items). Items were scored on a 5 point Likert-type response scale: 0=never a problem to 1=almost never a problem; 2=sometimes a problem; 3=often a problem; and 4=almost always a problem). Once scored, items were reverse scored and linearly transformed to a 0-100 scale (0=100, 1=75, 2=50, 3=25, 4=0), where higher scores indicated better HRQOL. Total Scale Score was the sum of all the items over the number of items answered on all the Scales. Baseline was defined as the last measurement before first intake of study treatment on Day 1.

Time frame:
Baseline (Day 1), Day 85
Reported as:
Mean · units on a scale
Pharmacodynamics - Change From Baseline in Pediatric Quality of Life (PedsQL™) (Version 4.0) Generic Core Scales at Day 85
units on a scaleElafibranor 80 mgElafibranor 120 mg
Parent-3.80 ± 13.76-13.04 ± 11.32
Participants-3.04 ± 1.42-3.04 ± 9.01
SecondaryNumber of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious TEAEs

An adverse event (AE) was any untoward medical in a participant or clinical investigation patient administered a pharmaceutical (investigational) product and which does not necessarily have to have a causal relationship with this treatment. A Serious adverse event (SAE) was any untoward medical occurrence that at any dose: resulted in death, was life-threatening, required inpatient hospitalization/prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, was another medically important condition. TEAEs were defined as AEs that started prior to first study drug dose and that worsened after, and the AEs that started on or after first study drug dose. TEAEs: Serious and non-serious AEs.

Time frame:
From Screening visit (signature of informed consent) up to last dose of study drug + 30 days (i.e., up to Day 113)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious TEAEs
ParticipantsElafibranor 80 mgElafibranor 120 mg
Participants with TEAEs20
Participants with Serious TEAEs00
SecondaryNumber of Participants With Clinically Significant Abnormalities in 12-lead Electrocardiogram (ECG) Measurement

ECG measurements were taken with the participants in resting position for at least 10 minutes. The investigator determined whether abnormal assessment results were clinically significant or not. The number of participants with abnormal clinically significant ECG findings were reported. Baseline was defined as the last measurement before first intake of study treatment on Day 1.

Time frame:
Baseline (Day 1), Day 85
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Abnormalities in 12-lead Electrocardiogram (ECG) Measurement
ParticipantsElafibranor 80 mgElafibranor 120 mg
Baseline (Day1): Abnormal, clinically significant00
Day 85: Abnormal, clinically significant00
SecondaryNumber of Participants With Abnormal Clinical Chemistry Parameters

Fasting blood samples (collected after 10 hours fasting) were used to assess the following clinical chemistry parameters: creatinine, glomerular filtration rate, creatinine clearance, total proteins, albumin, electrolytes (sodium, potassium, chloride, calcium), uric acid, urea nitrogen, urea, creatine phosphokinase (CPK), AST, ALT, GGT, ALP, total and conjugated bilirubin, high sensitivity C-reactive protein, fasting plasma glucose, fasting insulin, HOMA-IR, fructosamine, C-peptide, free fatty acids, glycated hemoglobin A1c, cystatin C. Abnormal clinical chemistry values were classified based on reference range: lower limit of normality (LLN); normal (\>= LLN and \<= upper limit of normality \[ULN\]); \> ULN and \<3 ULN; \>=3 ULN and \<5 ULN and \>=5 ULN. Only the parameters for which at least one value of abnormality were reported and presented in this outcome measure.

Time frame:
At Day 85 (i.e., end of treatment)
Reported as:
Count of participants · Participants
Number of Participants With Abnormal Clinical Chemistry Parameters
ParticipantsElafibranor 80 mgElafibranor 120 mg
Total proteins: >ULN and <3 ULN11
Albumin: >ULN and <3 ULN10
CPK: >ULN and <3 ULN01
AST: >ULN and <3 ULN30
ALT: >ULN and <3 ULN34
ALT: >=3 ULN and <5 ULN10
ALT: >=5 ULN10
GGT: >ULN and <3 ULN22
GGT: >=3 ULN and <5 ULN10
GGT: >=5 ULN10
ALP: >ULN and <3 ULN10
Total Bilirubin: >ULN and <3 ULN01
Conjugated Bilirubin: >ULN and <3 ULN01
C Reactive Protein: >ULN and <3 ULN01
Fasting plasma glucose: >ULN and <3 ULN10
Fasting insulin: >ULN and <3 ULN35
Fasting insulin: >=3 ULN and <5 ULN20
C-peptide: >ULN and <3 ULN42
Hemoglobin A1C: >ULN and <3 ULN10
SecondaryNumber of Participants With Abnormal Hematology and Coagulation Parameters

Fasting blood samples (collected after 10 hours fasting) were used to assess the following hematology and coagulation parameters: hemoglobin, hematocrit, red blood cells (RBC), white blood cells (WBC), neutrophils, eosinophils, basophils, lymphocytes, monocytes, platelets, prothrombin time (PT) and international normalized ratio (INR). Hematology and coagulation values were classified based on the reference range: LLN; normal (\>= LLN and \<= ULN); \> ULN and \<3 ULN; \>=3 ULN and \<5 ULN and \>=5 ULN.

Time frame:
At Day 85 (i.e., end of treatment)
Reported as:
Count of participants · Participants
Number of Participants With Abnormal Hematology and Coagulation Parameters
ParticipantsElafibranor 80 mgElafibranor 120 mg
Haemoglobin: >ULN and <3 ULN00
Hematocrit: >ULN and <3 ULN00
RBC: >ULN and <3 ULN01
WBC: >ULN and <3 ULN00
Neutrophils: >ULN and <3 ULN00
Eosinophils: >ULN and <3 ULN00
Basophils: >ULN and <3 ULN00
Lymphocytes: >ULN and <3 ULN00
Monocytes: >ULN and <3 ULN00
Platelets: >ULN and <3 ULN00
PT: >ULN and <3 ULN00
INR: >ULN and <3 ULN00
SecondaryNumber of Participants With Abnormal Urinalysis Parameters

Blood samples were collected to assess the following urinalysis parameters: alpha-1 macroglobulin, N-acetyl glucosamide, neutrophil gelatinase-associated lipocalin, albumin, and creatinine. Abnormal urinalysis values were classified based on the reference range: LLN; normal (\>= LLN and \<= ULN); \> ULN and \<3 ULN; \>=3 ULN and \<5 ULN and \>=5 ULN.

Time frame:
At Day 85 (i.e., end of treatment)
Reported as:
Count of participants · Participants
Number of Participants With Abnormal Urinalysis Parameters
ParticipantsElafibranor 80 mgElafibranor 120 mg
Alpha-1 Microglobulin: >ULN and <3 ULN00
N-Acetyl Glucosamide: >ULN and <3 ULN00
Neutrophil Gelatinase-associated: >ULN and <3 ULN00
Albumin: : >ULN and <3 ULN00
Creatinine00
SecondaryNumber of Participants With Abnormal Vital Signs

Vital signs were taken before any invasive procedures. Following vital signs were assessed: systolic blood pressure, diastolic blood pressure, heart rate. Abnormal vita signs was defined as any abnormal findings in the vital sign parameters and were categorized as 'abnormal, not clinically significant (NCS)' and 'abnormal, clinically significant (CS)'.

Time frame:
At Day 85 (i.e., end of treatment)
Reported as:
Count of participants · Participants
Number of Participants With Abnormal Vital Signs
ParticipantsElafibranor 80 mgElafibranor 120 mg
Systolic Blood Pressure:Abnormal, not clinically significant00
Systolic Blood Pressure: Abnormal, clinically significant00
Diastolic Blood Pressure: Abnormal, not clinically significant00
Diastolic Blood Pressure: Abnormal, clinically significant00
Heart Rate: Abnormal, not clinically significant00
Heart Rate: Abnormal, clinically significant00
SecondaryNumber of Participants With Clinically Significant Abnormalities in Physical Examination at Baseline, Days 15, 29, 57, 85, and 113

Physical examination findings were collected according to pre-defined body systems: general appearance; skin; eyes; ears; nose; throat; neck and thyroid; lungs; heart; upper/lower extremities; lymph nodes; abdomen; musculoskeletal system; basic neurological assessment. Additional systems were evaluated as needed. Clinical significance was defined as any variation in assessment results that had medical relevance resulting in an alteration in medical care. Participants with at least one clinically significant abnormality in physical examination were reported and presented in this outcome measure. Baseline was defined as the last measurement before first intake of study treatment on Day 1.

Time frame:
Baseline (Day 1), Days 15, 29, 57, 85, and 113
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Abnormalities in Physical Examination at Baseline, Days 15, 29, 57, 85, and 113
ParticipantsElafibranor 80 mgElafibranor 120 mg
Baseline (Day 1)42
Day 1500
Day 2910
Day 5700
Day 8500
Day 11300

Adverse events

Collected over All AEs were collected from screening through 30 days after last dose of study drug (i.e., up to Day 113) regardless of seriousness or relationship to study drug.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Elafibranor 80 mg0/5 (0%)0/5 (0%)2/5 (40%)
Elafibranor 120 mg0/5 (0%)0/5 (0%)0/5 (0%)
Most frequent other events
Most frequent other events
EventElafibranor 80 mgElafibranor 120 mg
HepatomegalyHepatobiliary disorders1/50/5
Gastroenteritis viralInfections and infestations1/50/5
AsthmaRespiratory, thoracic and mediastinal disorders1/50/5

Baseline characteristics

Analysis was performed on intent-to-treat (ITT) population that had included participants who were randomized and had received at least 1 dose of the study drug.

Age, Continuous
Age, Continuous(years)Elafibranor 80 mgElafibranor 120 mgTotal
Mean14.52 ± 2.2315.70 ± 2.3115.11 ± 2.23
Sex: Female, Male
Sex: Female, Male(Participants)Elafibranor 80 mgElafibranor 120 mgTotal
Female000
Male5510
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Elafibranor 80 mgElafibranor 120 mgTotal
Hispanic or Latino459
Not Hispanic or Latino101
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Elafibranor 80 mgElafibranor 120 mgTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American000
White235
More than one race000
Unknown or Not Reported325
08

Study locations

2 sites
  • University of California
    San Diego, California 92103, United States
  • Columbia University
    New York, New York 10032, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2019 to primary completion in Jun 2020, 11 months.

Results were first posted in Oct 2021, 1 year 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 13, 2019
First posted
Mar 21, 2019
StartActual
Jun 25, 2019
Primary completionActual
Jun 16, 2020
CompletionActual
Jun 16, 2020
Results first posted
Oct 28, 2021
Last update
Oct 28, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 28, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03883607
Lead sponsor
Genfit
Responsible party
Sponsor
First posted
Mar 21, 2019
Start date
Jun 25, 2019
Primary completion
Jun 16, 2020
Completion
Jun 16, 2020
Results posted
Oct 28, 2021
Last update
Oct 28, 2021

Study contacts

Carol Addy, MD MMSc
study director · Genfit

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Elifibranor

Start the discussion